Menopur (Menotrophin)

Menotropin supplies both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) derived from post‑menopausal urine. After injection, FSH binds to receptors on ovarian granulosa cells, encouraging follicular growth, while LH activates theca cells and luteal tissue to produce steroids, together supporting follicle maturation, ovulation, or sperm production in men.

The dose of Menopur is individualized; a prescribing clinician determines the amount and schedule based on the patient’s ovarian response, body weight, and treatment protocol. Dosing may be adjusted during the stimulation cycle according to ultrasound monitoring and hormone levels.

Menopur is intended for use before conception to induce ovulation; it is not administered during an established pregnancy. Safety data for use while breastfeeding are limited, and the product is generally avoided in nursing mothers unless the benefits outweigh potential risks as assessed by the treating physician.

To order Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Menopur differs from recombinant FSH products by providing a combination of FSH and LH activity in a single preparation, which can simplify dosing for patients who need both hormones. Recombinant preparations offer pure FSH without LH, requiring an additional LH source if needed. Choice depends on clinical protocol, patient response, and physician preference.

Menopur should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use, and allow the product to reach room temperature briefly before reconstitution, following aseptic technique to maintain sterility.

Menopur is supplied as a lyophilized powder that must be reconstituted with a sterile diluent. The resulting solution is injected subcutaneously or intramuscularly, typically in the abdomen or thigh, according to the dosing schedule prescribed by the clinician. Proper injection technique and site rotation help minimize local reactions.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause rapid ovarian enlargement, fluid shifts, and, in severe cases, thromboembolism or renal failure. Multiple pregnancy is another significant concern, as the drug can increase the likelihood of twins or higher‑order gestations. Prompt monitoring is essential to detect these complications early.

Menopur is contraindicated in individuals with known hypersensitivity to menotropin or any component of the formulation, in patients with active ovarian cysts, uncontrolled thyroid disease, or severe ovarian failure. It should also be avoided in women who are already pregnant, have ovarian hyperstimulation syndrome, or have a history of thromboembolic disorders unless a specialist determines the benefits outweigh the risks.